 Home > Active Ingredient News > Immunology News > ARD: EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome

ARD: EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome

 Last Update: 2022-08-16
 Source: Internet
 Author: User

Tags

hydroxychloroquine 200 mg

serum uric acid

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Purpose : For gout, vasculitis, systemic sclerosis (SSc) , myositis, mixed connective tissue disease (MCTD) , Sjögren's syndrome (SS) , systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) Develop recommendations for cardiovascular risk (CVR) managemen.

Objective : To treat gout, vasculitis, systemic sclerosis (SSc) , myositis, mixed connective tissue disease (MCTD) , Sjögren's syndrome (SS) , systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS.

METHODS : Following the European League Against Rheumatism (EULAR) standardized procedure, a multidisciplinary working group developed recommendations for CVR prediction and management based on systematic literature review and expert opini.

Methods : Following the European League Against Rheumatism (EULAR) standardized procedures, a multidisciplinary working group developed recommendations for CVR prediction and management based on systematic literature review and expert opini.

RESULTS : Four overarching principles emphasized the need for regular screening and management of modifiable CVR factors and patient educati.

Conclusions Conclusions : These recommendations can guide clinical practice and future research to improve cardiovascular risk management in rheumatic and musculoskeletal disease.

Source: Drosos GC, Vedder D, Houben E , et a.
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndro.
Annals of the Rheumatic Diseases2022; 81: 768-77 , et al Annals of the Rheumatic Diseases81: Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top Quality 99.9% Ritlecitinib Tosylate Immunoregulation API & Inflammation Inhibitor

CAS No.: 2192215-81-7

Pharmacy Grade; Food Grade

$200-250/G FOB

β-Alanine107-95-9

CAS No.: 107-95-9

$1-1.1/KG FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.